Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Brandes Investment Partners LP

Brandes Investment Partners LP grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 47.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,651,265 shares of the company's stock after purchasing an additional 849,229 shares during the quarter. Brandes Investment Partners LP owned approximately 0.08% of Takeda Pharmaceutical worth $37,834,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. XY Capital Ltd lifted its position in Takeda Pharmaceutical by 432.5% during the fourth quarter. XY Capital Ltd now owns 765,137 shares of the company's stock worth $10,919,000 after buying an additional 621,440 shares during the period. QRG Capital Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth about $5,511,000. Van ECK Associates Corp boosted its position in shares of Takeda Pharmaceutical by 21.6% in the third quarter. Van ECK Associates Corp now owns 1,278,300 shares of the company's stock worth $19,775,000 after acquiring an additional 226,754 shares during the last quarter. HAP Trading LLC grew its holdings in Takeda Pharmaceutical by 543.4% in the third quarter. HAP Trading LLC now owns 263,679 shares of the company's stock valued at $4,079,000 after purchasing an additional 222,700 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Takeda Pharmaceutical during the third quarter worth approximately $2,105,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Up 0.5 %

Shares of TAK traded up $0.06 during trading hours on Monday, hitting $13.28. The stock had a trading volume of 594,399 shares, compared to its average volume of 1,757,529. The firm has a market cap of $42.03 billion, a P/E ratio of 24.15, a P/E/G ratio of 3.24 and a beta of 0.56. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.58 and a current ratio of 1.11. The company's fifty day simple moving average is $13.63 and its 200 day simple moving average is $14.07. Takeda Pharmaceutical Company Limited has a 12-month low of $12.77 and a 12-month high of $16.47.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.